Ground Swell Capital’s Genetic Technologies Ltd. GENE Stock Holding History

Ground Swell Capital’s Portfolio GENE Stock Details GENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,533	Closed	-$26K	–	197
2022 Q2	$26K	Buy	+4,533	New	+$32.8K	0.05%	106

Other funds holding GENE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ground Swell Capital's GENE Position: Q3 2022 in Review

Ground Swell Capital sold out of Genetic Technologies Ltd. (GENE) in Q3 2022, closing a stake of 4,533 shares — an estimated $26K sold.

Ground Swell Capital first reported a position in GENE in Q2 2022 and held it in 1 quarter. The position peaked at $26K in Q2 2022. 10 funds tracked by Wall St. Rank hold GENE as of Q3 2022.

Ground Swell Capital reported no remaining Genetic Technologies Ltd. position as of Q3 2022 after selling out during the quarter.
Ground Swell Capital sold 4,533 Genetic Technologies Ltd. shares in Q3 2022, an estimated $26K.
Ground Swell Capital first reported a position in Genetic Technologies Ltd. in Q2 2022 and held it in 1 quarter.
Ground Swell Capital's Genetic Technologies Ltd. position peaked at $26K in Q2 2022.
10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2022.

Based on Ground Swell Capital's 13F filing for Q3 2022, filed 14 Nov 2022.